3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid — Drug Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

2 Countries

Phase I

Phase I (Other)

Other

Phase I: 1 Phase I (Other): 1 Other: 1

Oversight events:

2 corrective measures across 2 trials

Indications tested

3 total

PHASE Ib STUDY WITH THE COMBINATION OF LB–100 (PP2A INHIBITOR) AND ATEZOLIZUMAB (PD–L1 INHIBI-TOR) IN METASTATIC COLORECTAL CANCER PATIENTS … Recruiting

2023-505534-98-00 Phase I 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
LB−100 and azenosertib in metastatic colorectal cancer patients Suspended

2024-511227-33-00 Phase I (Other) 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ended

2024-510877-67-00 1 country Asoc Grupo Espanol De Investigacion En Sarcomas

Showing 1–3 of 3 trials